Literature DB >> 9070625

Cardiovascular effects of neurotensin microinjections into the nucleus of the solitary tract.

J Ciriello1, T X Zhang.   

Abstract

Neurotensin (NT) immunoreactivity and binding sites have been demonstrated to be extensively distributed throughout the caudal nucleus of the solitary tract (NTS). In this study, the cardiovascular effects of microinjecting the tridecapeptide neurotensin (NT) or its analogues NT 1-8 and [D-Trp11]NT into NTS were investigated in the chloralose-anesthetized, paralyzed and artificially ventilated rat. Microinjection of NT (10 pmol) elicited decreases in arterial pressure (AP) (-34 +/- 3 mm Hg) and heart rate (HR) (-28 +/- 2 beats/min), whereas microinjection of equimolar amounts of the NT fragment NT 1-8 elicited a significantly smaller depressor response (-14 +/- 3 mm Hg), but the bradycardic (-22 +/- 4 beats/min) response was similar in magnitude to that elicited by NT. On the other hand, microinjection of [D-Trp11]NT did not elicit cardiovascular responses from sites in NTS. In addition, the prior injection of [D-Trp11]NT into cardiovascular responsive sites in the NTS did not significantly reduce the AP or HR response to NT. The depressor response elicited by NT was not affected by bilateral vagotomy but was abolished by either C1-C2 spinal cord transection or the i.v. administration of the nicotinic receptor blocker hexamethonium bromide. The cardiac slowing was partially attenuated by either bilateral vagotomy (-19 +/- 2 beats/min), i.v. administration of atropine methyl bromide (-17 +/- 4 beats/min), i.v. administration of hexamethonium bromide (-11 +/- 4 beats/min) or by spinal cord transection (-12 +/- 3 beats/min), and completely abolished after total autonomic blockade or by combined bilateral vagotomy and spinal cord transection. These data have demonstrated that within a restricted region of the caudal NTS NT activates neurons that contribute to vasodepressor responses as a result of sympatho-inhibition and to bradycardia responses as a result of vagal excitation and sympatho-inhibition. Furthermore, these data suggest that NT may act as a neurotransmitter or modulator in central cardiovascular reflex pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070625     DOI: 10.1016/s0006-8993(96)01176-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Intrathecal neurotensin is hypotensive, sympathoinhibitory and enhances the baroreflex in anaesthetized rat.

Authors:  B Zogovic; P M Pilowsky
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

4.  Pro-neurotensin/Neuromedin N and Hypertension Risk: A Prospective Study.

Authors:  Charles D Nicoli; D Leann Long; Timothy B Plante; George Howard; Suzanne E Judd; Janin Schulte; Mary Cushman
Journal:  Am J Hypertens       Date:  2022-03-08       Impact factor: 3.080

5.  Effects of bilateral adrenalectomy on systemic kainate-induced activation of the nucleus of the solitary tract. Regulation of blood pressure and local neurotransmitters.

Authors:  Merari F R Ferrari; Debora R Fior-Chadi; Gerson Chadi
Journal:  J Mol Histol       Date:  2008-01-15       Impact factor: 2.611

6.  Activation of ventral tegmental area neurotensin Receptor-1 neurons promotes weight loss.

Authors:  Patricia Perez-Bonilla; Krystal Santiago-Colon; Jillian Matasovsky; Jariel Ramirez-Virella; Rabail Khan; Hannah Garver; Gregory Fink; Anne M Dorrance; Gina M Leinninger
Journal:  Neuropharmacology       Date:  2021-06-09       Impact factor: 5.273

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.